Genus PLC
LSE:GNS

Watchlist Manager
Genus PLC Logo
Genus PLC
LSE:GNS
Watchlist
Price: 1 776 GBX -1.88% Market Closed
Market Cap: 1.2B GBX
Have any thoughts about
Genus PLC?
Write Note

Relative Value

The Relative Value of one GNS stock under the Base Case scenario is 3 002.33 GBX. Compared to the current market price of 1 776 GBX, Genus PLC is Undervalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GNS Relative Value
Base Case
3 002.33 GBX
Undervaluation 41%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
85
vs Industry
83
Median 3Y
2.6
Median 5Y
3.2
Industry
8.1
Forward
1.7
vs History
7
vs Industry
5
Median 3Y
48.4
Median 5Y
56.9
Industry
23
Forward
24.3
vs History
52
vs Industry
7
Median 3Y
44.6
Median 5Y
44
Industry
23.4
vs History
66
vs Industry
1
Median 3Y
112.1
Median 5Y
97.7
Industry
27.3
vs History
85
vs Industry
45
Median 3Y
2.9
Median 5Y
3.4
Industry
2.6
vs History
84
vs Industry
70
Median 3Y
2.9
Median 5Y
3.4
Industry
8.1
Forward
2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
84
vs Industry
8
Median 3Y
17.9
Median 5Y
22.1
Industry
4.3
Forward
12.2
vs History
79
vs Industry
5
Median 3Y
31.8
Median 5Y
37.2
Industry
3.8
Forward
18.8
vs History
36
vs Industry
6
Median 3Y
49.9
Median 5Y
46.2
Industry
6
vs History
7
vs Industry
2
Median 3Y
95.9
Median 5Y
95.9
Industry
3.8
vs History
77
vs Industry
53
Median 3Y
2
Median 5Y
2.5
Industry
4.8

Multiples Across Competitors

GNS Competitors Multiples
Genus PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Genus PLC
LSE:GNS
1.2B GBP 1.8 148.5 13.9 25.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
301B USD 5.4 59.2 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
162B USD 5 38.3 17.8 33.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.5B USD 12 -265.7 26.9 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
115.4B USD 4.1 916 10.2 10.2
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
138B AUD 6 33.9 20.9 26
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.6B USD 6.4 19 17.5 19.4
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
UK
Genus PLC
LSE:GNS
Average P/E: 202.5
148.5
805%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59.2
412%
US
Amgen Inc
NASDAQ:AMGN
38.3
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -265.7
42%
US
Gilead Sciences Inc
NASDAQ:GILD
916
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
UK
Genus PLC
LSE:GNS
Average EV/EBITDA: 17.4
13.9
35%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.8
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.9
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
UK
Genus PLC
LSE:GNS
Average EV/EBIT: 23.7
25.9
78%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.7
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
26
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top